BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by unexplained ...
We quantified the proportion of diagnoses of pulmonary fibrosis (PF) among 25 136 people with lung cancer and 250 583 matched ...
After his brother's diagnosis, columnist Sam Kirton has new questions about the nature of familial idiopathic pulmonary fibrosis.
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Idiopathic Pulmonary Fibrosis (IPF) leads to thickening and stiffening of lung tissue, impairing gas exchange and causing ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF). The main end point in the study was lung function based ...
The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback